Claims for Patent: 4,521,405

Summary for Patent: 4,521,405

Title:	Methods and materials for treatment of disease states involving immunological factors
Abstract:	In animals including humans, the symptoms of non-anaphylactic disease states wherein the disease victim\'s humoral and/or cell-mediated immunological response is involved in disease pathology are alleviated upon administration of compositions comprising mixtures of histamine and one or more immunogenic substances participative in the humoral or cell-mediated pathogenic response. In preferred embodiments, the compositions are administered in essentially minute, \"neutralizing\" doses. Illustratively, significant relief of symptoms of multiple sclerosis is achieved through parenteral (e.g., subcutaneous of sublingual) administration of mixtures of histamine and measles virus immunogen. For a majority of patients, from about 8.8.times.10.sup.-6 to 5.5.times.10.sup.-3 mg of histamine phosphate will provide an effective quantity of histamine to a unit dose of the mixture. Likewise, a unit dose of the mixture will contain from about 2.times.10.sup.-3 to about 4.times.10.sup.-4 times the prescribed vaccination dose of a killed, attenuated measles virus vaccine strain. As another example, rheumatoid arthritis symptoms are alleviated by administration of histamine admixed with an immunoglobulin G immunogen which is provocative of in vivo rheumatoid factor production. Other immune disorders (e.g., chronic pain and herpes simplex type II infections) are effectively treated with admixtures of histamine and appropriate immunogen(s).
Inventor(s):	McMichael; John (Cambridge Springs, PA)
Assignee:	McMichael; John (Cambridge Springs, PA)
Application Number:	06/378,752
Patent Claims:	1. A method for alleviating the symptoms of a multiple sclerosis disease state comprising administering to the disease victim an effective amount of a composition comprising a mixture of histamine and inactivated, attenuated measles virus or an immunologically active fraction thereof. 2. The method of claim 1 wherein the measles virus is an inactivated, attenuated vaccine strain. 3. The method of claim 1 wherein said composition comprises, in a unit dosage form, from about 2.times.10.sup.-3 to about 4.times.10.sup.-4 times the prescribed vaccination dose of an inactivated, attenuated measles virus vaccine strain. 4. The method of claim 1 wherein histamine is administered in the form of a water soluble histamine salt. 5. The method of claim 1 wherein the composition comprises, in unit dosage form, from about 8.8.times.10.sup.-6 mg to about 5.5.times.10.sup.-3 mg of histamine phosphate. 6. The method of claim 1 wherein said composition is administered parenterally. 7. The method of claim 1 wherein said composition is administered subcutaneously or sublingually. 8. A composition of matter useful in alleviating the symptoms of a non-anaphylactic disease state wherein the disease victim's humoral and/or cell mediated immunological response is participative in the disease pathology, said composition comprising an effective amount of a mixture of histamine and inactivated, attenuated measles virus. 9. A composition of matter according to claim 8 wherein the measles virus is an effective amount of an inactivated, attenuated vaccine strain.

Details for Patent 4,521,405

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alk-abello, Inc.	HISTATROL	positive skin test control-histamine	Injection	103754	September 29, 1950	4,521,405	2040-01-29
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	4,521,405	2040-01-29